Poster Presentation Clinical Oncology Society of Australia 2014 Annual Scientific Meeting

Nivolumab and ipilimumab in first-line non-small-cell lung carcinoma (NSCLC): interim phase I results (#294)

Scott J Antonia 1 , Scott Gettinger 2 , Laura Q Chow 3 , Rosalyn Juergens 4 , Hossein Borghaei 5 , Yun Shen 6 , Christopher Harbison 6 , Allen C Chen 6 , Neal E Ready 7 , Naiyer A Rizvi 8
  1. H. Lee Moffitt Cancer Centre & Research Institute, Tampa, FL, USA
  2. Yale Cancer Center, New Haven, CT, USA
  3. University of Washington, Seattle, WA, USA
  4. Juravinski Cancer Centre at McMaster University, Hamilton, ON, Canada
  5. Fox Chase Cancer Centre, Philadelphia, PA, USA
  6. Bristol-Myers Squibb, Princeton, NJ, USA
  7. Duke University Medical Centre, Durham, NC, USA
  8. Memorial Sloan-Kettering Cancer Centre, New York, NY, USA

Aims: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, and ipilimumab, a fully human IgG1 Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) immune checkpoint receptor blocking antibody, have shown activity in advanced NSCLC; clinical data in melanoma showed improvement in survival and manageable safety profile when combined. We report interim results from phase I study evaluating first-line nivolumab + ipilimumab (N+I) combination in advanced NSCLC patients (pts). Methods: Chemotherapy-naïve pts (n=46) with squamous (sq) or non-sq NSCLC received the 3N+1Img/kg or 1N+3Img/kg combination dose IV every 3 weeks for 4 cycles followed by nivolumab 3mg/kg IV fortnightly until progression/unacceptable toxicity. Safety and Objective response rate (ORR; RECIST 1.1) were evaluated overall and by baseline tumour PD-ligand-1 (PD-L1) status (Dako immunohistochemistry assay).
Results: In the 4 cohorts with ≥4 months follow up, any-grade treatment-related adverse events (managed with protocol algorithms) were reported in 39 pts (85%; grade 3–4 in 22 pts [48%]) and led to discontinuation in 16 pts. Treatment-related deaths (n=3) were due to respiratory failure following colitis, bronchopulmonary hemorrhage and toxic epidermal necrolysis. Across all cohorts: 1+3mg/kg sq, 1+3mg/kg non-sq, 3+1mg/kg sq, 3+1mg/kg non-sq, the confirmed objective response rates (ORR) were 11%, 13%, 33% and 13%, respectively. Overall ORR (confirmed and unconfirmed) was 22% (median duration of response [mDOR] not reached [NR]) and stable disease (SD) 33% (range 22-56 weeks); 3 pts exhibited unconventional “immune related” responses. In 38 evaluable tumour samples from the study, ORR did not correlate with PD-L1 status. Conclusions: These interim data in pts with advanced NSCLC suggest that a nivolumab + ipilimumab immunotherapy regimen is feasible and demonstrates antitumor activity in both PD-L1+ and PD-L1– pts. Safety will be further assessed at additional specified doses and schedules.